Coherus BioSciences (NASDAQ:CHRS) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Coherus BioSciences (NASDAQ:CHRS) from a hold rating to a sell rating in a research report released on Tuesday morning.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $5.38.

Coherus BioSciences Stock Performance

Shares of CHRS stock opened at $1.12 on Tuesday. Coherus BioSciences has a fifty-two week low of $0.66 and a fifty-two week high of $2.43. The company has a market cap of $129.80 million, a PE ratio of -14.00 and a beta of 1.01. The stock’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.12.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CHRS. Steph & Co. acquired a new position in Coherus BioSciences in the 4th quarter worth about $34,000. Bank of Montreal Can acquired a new position in shares of Coherus BioSciences in the fourth quarter valued at approximately $34,000. Intech Investment Management LLC bought a new position in Coherus BioSciences in the 4th quarter valued at approximately $38,000. Wealth Enhancement Advisory Services LLC raised its holdings in Coherus BioSciences by 97.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 15,214 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Coherus BioSciences during the 4th quarter worth approximately $52,000. 72.82% of the stock is currently owned by institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.